Vivex® Biologics, Inc. Appoints Industry Veteran Jon E. Block, Ph.D., as Chief Clinical Officer
Dr. Jon Block to Lead Vivex’s Completion of its Ascend and Restore Randomized Clinical Trials for VIA Disc® NP, Vivex’s...
Clinical Trial
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as...
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in...
Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized dosing and therapeutic support for...
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its...
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday,...
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growthHOUSTON, June 09,...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer...
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed...
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences...
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan DrugPhiladelphia, Pennsylvania--(Newsfile Corp....
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered...
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and...
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been...
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with...
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
- Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June...
Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results, Net profit rises 34.2% year-on-year
BEIJING, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance...
Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
First-in-class agent targets WISP1 in patients with IPF Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC)...
Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results
BEIJING, June 5, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated...